-transparent.png){kind=logo}
13 patients with polyosseous Paget's disease were treated for a mean period of 7 months with disodium etidronate (EHDP, ethylidene-1-hydroxy-1,1-diphosphonate); the average daily dosage was 5 mg/kg body weight. Subjectively, all patients reported a considerable improvement, in particular with regard to pain. Objectively, a significant decrease in plasma alkaline phosphatase activity and in urinary hydroxyproline excretion was observed. Bone scintigraphy showed a decreased activity of bone lesions after therapy, but no clear-cut regression was found radiologically. No serious side-effects were observed during treatment with EHDP and oral administration of the drug proved to be advantageous.
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
November 1986,
Wiener medizinische Wochenschrift (1946),
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
June 1974,
Calcified tissue research,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
September 1987,
Atherosclerosis,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
January 1986,
Microbiology and immunology,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
September 1973,
Experientia,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
January 1982,
Experimental pathology,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
September 1974,
Clinical science and molecular medicine,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
April 1983,
Clinical orthopaedics and related research,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
July 1974,
Clinical science and molecular medicine,
J Kovarik, and
B Niebauer, and
W Woloszczuk, and
F Frühwald, and
H Kolbe
January 1993,
Pediatric radiology,
